TW202233637A - 作為egfr抑制劑之經取代1h-吡唑并[4,3-c]吡啶及衍生物 - Google Patents

作為egfr抑制劑之經取代1h-吡唑并[4,3-c]吡啶及衍生物 Download PDF

Info

Publication number
TW202233637A
TW202233637A TW110140534A TW110140534A TW202233637A TW 202233637 A TW202233637 A TW 202233637A TW 110140534 A TW110140534 A TW 110140534A TW 110140534 A TW110140534 A TW 110140534A TW 202233637 A TW202233637 A TW 202233637A
Authority
TW
Taiwan
Prior art keywords
alkyl
group
membered
cycloalkyl
independently selected
Prior art date
Application number
TW110140534A
Other languages
English (en)
Chinese (zh)
Inventor
哈拉德 英傑爾哈德特
馬克 彼得羅茨基
吉爾金 雷哈特
奧理奇 雷瑟爾
海恩茲 史塔德慕勒
德克 沙恩
托比亞斯 沃伯格
Original Assignee
德商百靈佳殷格翰國際股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 德商百靈佳殷格翰國際股份有限公司 filed Critical 德商百靈佳殷格翰國際股份有限公司
Publication of TW202233637A publication Critical patent/TW202233637A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW110140534A 2020-11-02 2021-11-01 作為egfr抑制劑之經取代1h-吡唑并[4,3-c]吡啶及衍生物 TW202233637A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20205297 2020-11-02
EP20205297.3 2020-11-02

Publications (1)

Publication Number Publication Date
TW202233637A true TW202233637A (zh) 2022-09-01

Family

ID=73059474

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110140534A TW202233637A (zh) 2020-11-02 2021-11-01 作為egfr抑制劑之經取代1h-吡唑并[4,3-c]吡啶及衍生物

Country Status (7)

Country Link
US (2) US12064421B2 (OSRAM)
EP (1) EP4237423B1 (OSRAM)
JP (1) JP7805363B2 (OSRAM)
CN (1) CN116507627B (OSRAM)
AR (1) AR123977A1 (OSRAM)
TW (1) TW202233637A (OSRAM)
WO (1) WO2022090481A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3213079A1 (en) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Amino-substituted heterocycles for treating cancers with egfr mutations
KR20240133663A (ko) * 2023-02-28 2024-09-04 보로노이 주식회사 헤테로아릴 유도체 및 이의 용도
KR20240152239A (ko) * 2023-04-11 2024-10-21 보로노이 주식회사 피라졸로피리딘 유도체 화합물 및 이의 용도
CN117069746B (zh) * 2023-08-17 2025-10-21 苏州共康医药科技有限公司 取代的吡唑并吡啶类化合物作为4代egfr抑制剂

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7338959B2 (en) 2002-03-01 2008-03-04 Smithkline Beecham Corporation Diamino-pyrimidines and their use as angiogenesis inhibitors
AU2003226149A1 (en) 2002-04-05 2003-10-27 Merck & Co., Inc. Substituted aryl amides
JP2006528702A (ja) 2003-05-21 2006-12-21 プロシディオン・リミテッド グリコーゲンホスホリラーゼのピロロピリジン−２−カルボン酸アミドインヒビター
WO2006053166A1 (en) 2004-11-12 2006-05-18 Bristol-Myers Squibb Company 8h-imidazo[4,5-d]thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
US7737279B2 (en) 2005-05-10 2010-06-15 Bristol-Myers Squibb Company 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
TW200803855A (en) 2006-02-24 2008-01-16 Kalypsys Inc Quinolones useful as inducible nitric oxide synthase inhibitors
JP2010517970A (ja) 2007-02-02 2010-05-27 ノイロサーチ アクティーゼルスカブ ピリジニル−ピラゾール誘導体及びカリウムチャネル調節剤としてのそれらの使用
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
TWI501967B (zh) 2010-12-16 2015-10-01 Janssen R&D Ireland 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
WO2013056679A1 (en) 2011-10-21 2013-04-25 Beijing Hanmi Pharmaceutical Co., Ltd Novel heteroaryl-amino derivatives
AR090151A1 (es) 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
WO2013184766A1 (en) 2012-06-06 2013-12-12 Irm Llc Compounds and compositions for modulating egfr activity
CA2871388A1 (en) * 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag 5-azaindazole compounds and methods of use
KR20150060724A (ko) 2012-09-28 2015-06-03 머크 샤프 앤드 돔 코포레이션 Erk 억제제인 신규 화합물
EP3181564B1 (en) 2012-11-20 2019-09-18 H. Hoffnabb-La Roche Ag Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2014210354A1 (en) 2013-06-28 2014-12-31 Genentech, Inc. Azaindazole compounds as inhibitors of t790m containing egfr mutants
MX2016002241A (es) 2013-08-22 2016-05-31 Hoffmann La Roche Alcoholes de alquinilo y metodos de uso.
CN104418858B (zh) 2013-08-30 2018-12-11 浙江医药股份有限公司新昌制药厂 2,6-二含氮取代的嘌呤衍生物及其制备方法和其药物组合物与应用
US9546168B2 (en) 2013-12-18 2017-01-17 Merck Sharp & Dohme Corp. ERK inhibitors
SMT202400142T1 (it) 2014-01-13 2024-05-14 Aurigene Oncology Ltd Enantiomeri (r) e (s) di n-(5-(3-idrossipirrolidin-1-il)-2-morfolinoossazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4-il)ossazolo-carbossammide in qualità di inibitori di irak4 per il trattamento di un cancro
CA3175724C (en) 2014-03-20 2024-01-09 Capella Therapeutics, Inc. Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof
TWI705967B (zh) 2014-03-20 2020-10-01 美商卡佩拉醫療公司 苯并咪唑衍生物及其醫藥組合物及使用方法
CN105315285B (zh) * 2014-07-25 2017-12-08 上海海雁医药科技有限公司 2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途
EP3270694A4 (en) * 2015-02-17 2018-09-05 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN108012529A (zh) 2015-05-15 2018-05-08 诺华股份有限公司 治疗egfr突变的癌症的方法
EP3303334B1 (en) 2015-06-03 2021-06-02 Principia Biopharma Inc. Tyrosine kinase inhibitors
CA2987914C (en) 2015-06-30 2022-09-13 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
KR20180051624A (ko) 2015-09-11 2018-05-16 베링거 인겔하임 인터내셔날 게엠베하 피라졸릴 치환된 헤테로아릴 및 의약으로서의 이의 용도
TWI726968B (zh) * 2016-01-07 2021-05-11 開曼群島商Ｃｓ醫藥技術公司 Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑
SG11201903871TA (en) 2016-11-03 2019-05-30 Bristol Myers Squibb Co Substituted bicycle heterocyclic derivatives useful as romk channel inhibitors
CA3061053A1 (en) 2017-06-02 2018-12-06 Boehringer Ingelheim International Gmbh Anti-cancer combination therapy
PH12020550725B1 (en) 2017-12-02 2024-05-24 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
WO2019162323A1 (en) * 2018-02-21 2019-08-29 Boehringer Ingelheim International Gmbh New benzimidazole compounds and derivatives as egfr inhibitors
WO2020178316A1 (en) * 2019-03-05 2020-09-10 Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. S.P.A. 5- or 7-azaindazoles as beta-lactamase inhibitors

Also Published As

Publication number Publication date
EP4237423B1 (en) 2024-12-11
US20240358688A1 (en) 2024-10-31
WO2022090481A1 (en) 2022-05-05
US20220133734A1 (en) 2022-05-05
JP7805363B2 (ja) 2026-01-23
US12064421B2 (en) 2024-08-20
AR123977A1 (es) 2023-02-01
EP4237423A1 (en) 2023-09-06
CN116507627B (zh) 2026-01-23
CN116507627A (zh) 2023-07-28
JP2023550591A (ja) 2023-12-04

Similar Documents

Publication Publication Date Title
CN114728918B (zh) Rip1抑制性化合物及其制备和使用方法
US11174245B2 (en) Benzimidazole compounds and derivatives as EGFR inhibitors
EP3728254B1 (en) Benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors
JP6745856B2 (ja) Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体
JP7014736B2 (ja) がんの処置のためのピラゾロピリジン誘導体
JP6771464B2 (ja) Ｃｂｐおよび／またはｅｐ３００インヒビターとしての、４，５，６，７−テトラヒドロ−１ｈ−ピラゾロ［４，３−ｃ］ピリジン−３−アミン化合物
TW202340209A (zh) 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
TW202210474A (zh) 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
KR101961500B1 (ko) 세린/트레오닌 키나제 억제제
EP4237423B1 (en) Substituted 1h-pyrazolo[4,3-c]pyridines and derivatives as egfr inhibitors
CN115297861A (zh) 化合物及其用途
CN115551862B (zh) 肽基精氨酸脱亚胺酶的大环抑制剂
US20220380382A1 (en) New macrocyclic compounds and derivatives as egfr inhibitors
WO2015074081A1 (en) Benzopiperazine compositions as bet bromodomain inhibitors
CN110234637A (zh) 用作irak抑制剂的吡唑酰胺化合物
KR20190003699A (ko) 제스트 인핸서 상동체 2 억제제
JP2025515285A (ja) 大環状複素環及びその使用
JP6586463B2 (ja) ＰＩ３Ｋβ阻害剤としての複素環連結イミダゾピリダジン誘導体
WO2024264070A2 (en) Akt inhibitors